Vascular remodeling is central to the pathophysiology of hypertension and atherosclerosis. Recent evidence suggests that vasoconstrictive substances, such as angiotensin II (All), may function as a vascular smooth muscle growth promoting substance. To explore the role of the counterregulatory hormone, atrial natriuretic polypeptide (ANP) in this process, we examined the effect of ANP (alpha-rat ANP 11-281) on the growth characteristics of cultured rat aortic smooth muscle (RASM) cells. ANP (i0-' M) significantly suppressed the proliferative effect of 1% and 5% serum as measured by 3H-thymidine incorporation and cell number, confirming ANP as an antimitogenic factor. In quiescent RASM cells, ANP (10-7, 10-6 M) significantly suppressed the basal incorporations of 3H-uridine and leucine by 50 and 30%, respectively. ANP (10-7, 10-6 M) also suppressed AII-induced RNA and protein syntheses (by 3040%) with the concomitant reduction of the cell size. Furthermore, ANP also significantly attenuated the increase of 3H-uridine and leucine incorporations caused by transforming growth factor-#l (4 X 1011, 4 X 1010 M), a potent hypertrophic factor. These results indicate that ANP possesses an antihypertrophic action on vascular smooth muscle cells. Downregulation of protein kinase C by 24-h treatment with phorbol 12,13-dibutyrate did not inhibit ANP-induced suppression on 3H-uridine incorporation. Based on the observation that ANP was more potent than a ring-deleted analogue of ANP on inhibiting 3H-uridine incorporation, we conclude that the ANP's inhibitory effect is primarily mediated via the activation of a guanylate cyclase-linked ANP receptor(s). Indeed 8-bromo cGMP mimicked the antihypertrophic action of ANP. Accordingly, we speculate that in addition to its vasorelaxant and natriuretic effects, the antihypertrophic action of ANP observed in the present study may serve as an additional compensatory mechanism of ANP in hypertension. (J. Clin. Invest.
Introduction
Blood pressure homeostasis is achieved by a balance of vasoconstrictive and vasodilatory forces. The potent vasorelaxant and diuretic-natriuretic hormone, atrial natriuretic polypeptide (ANP)' (1) (2) (3) (4) , is an important counterregulatory substance to vasoconstrictive hormones, such as angiotensin II (All). In hypertension, the synthesis and secretion ofANP may be increased to compensate for the enhanced vasoconstriction. Indeed, plasma ANP levels are reported to be elevated both in patients with hypertension (5) and in several hypertensive animals, such as the spontaneously hypertensive rats (SHR) (6, 7) and deoxycorticosteroid acetate (DOCA)-salt rats (8) . Recently it has been demonstrated that chronic blockade of endogenous circulating ANP by the monoclonal antibody against ANP accelerates the development of hypertension in SHR and DOCA-salt rats. This result supports the compensatory role of ANP in hypertension and extends further the concept that augmented secretion of ANP could represent an antihypertensive deterrent mechanism (9) .
Excessive vascular smooth muscle cell growth has been highlighted recently in the pathophysiology of hypertension and atherosclerosis. Indeed, one of the hallmarks of chronic hypertension is a generalized increase in the smooth muscle mass of the blood vessel wall (10). While acute hypertensive models (such as aortic coarctation) or experimental injury models of atherosclerosis are characterized by vascular smooth muscle cell proliferation (hyperplasia) (11, 12 ) chronic hypertension models, such as the Goldblatt two-kidney one-clip hypertensive rats and SHR exhibit aortic smooth muscle cell hypertrophy with an increase in polyploidy without an increase in cell number (13, 14) .
Recent evidence suggests that in addition to several growth factors, such as platelet-derived growth factor (PDGF) and transforming growth factor-, (TGF-f3), circulating or paracrine-autocrine vasoactive peptides may influence vessel wall growth. For example, All enhances serum-stimulated proliferation of human aortic smooth muscle cells (15) , and induces hypertrophy in quiescent vascular smooth muscle cells in serum-free medium (16) . All has been also shown to stimulate the expression of the protooncogene, c-fos (17), one of the earliest genetic programs associated with growth. We demonstrated further that All can induce sequentially c-myc and PDGF mRNA expressions in these cultured vascular smooth muscle cells (18) . The in vivo data that the angiotensin-converting enzyme inhibitor captopril prevented smooth muscle cell growth to a much greater extent than propranolol or hydralazine for a similar reduction in blood pressure (19) supports the role of All in the promotion of vascular smooth muscle cell growth.
1. Abbreviations used in this paper: All, angiotensin II; ANP, atrial natriuretic polypeptide; DOCA, deoxycorticosteroid acetate; PDGF, platelet-derived growth factor; RASM, rat aortic smooth muscle; SHR, spontaneously hypertensive rats; TGF-fl, transforming growth factor-0.
Because ANP is known to be a physiological antagonist to AII in vasoconstriction, secretion of aldosterone (3, 4) , or several centrally mediated effects (20) , we hypothesize that ANP can also inhibit vascular smooth muscle cell growth, especially that induced by AII. In this study we examined the antigrowth properties of ANP on vascular smooth muscle cells. Indeed, our data suggest that ANP is an inhibitor of vascular smooth muscle cell growth to many factors (e.g. serum, angiotensin, and TGF-fi).
Materials and Methods
Cell culture. RASM cells (passage 5-10) were isolated and cultured according to the method ofOwens et al. (21) . They were maintained in 1:1 mixture of DME and Ham's F12 medium (Gibco, Grand Island, NY) with 10% FCS, penicillin (100 U/ml), streptomycin (100 4g/ml), and 25 mM Hepes, pH 7.4. Cells were incubated at 370C in a humidified atmosphere of95% air-5% CO2 with media changes every 2-3 d. In preparation for experiments, the cells were made quiescent by placing them for 48 h in a defined serum-free (DSF) medium containing insulin (5 X l0-' M) (Sigma Chemical Co., St. Louis, MO), transferrin (5 ug/ml) (Sigma Chemical Co.), and ascorbate (0.2 mM) (Sigma Chemical Co.). This medium has been shown to maintain smooth muscle cells in a quiescent, noncatabolic state and to promote expression of smooth muscle cell-specific contractile proteins for an extended period of time (21 Hypertrophic action ofAII on postconfluent RASM cells.
All exhibited concentration-dependent stimulatory effects on 3H-uridine and leucine incorporations in quiescent RASM cells with the maximal increase of 130% for 3H-uridine and 70% for 3H-leucine incorporations occurring at 100 nM. The half-maximal All concentration for these effects was -10 nM ( Fig. 1 B) . No further increase was observed at the higher concentration of All.
The time course of All-induced 3H-uridine and leucine incorporations is shown in Fig. 1 A. The stimulatory effect of All on RNA synthesis was first observed after incubation for 4-8 h, and on protein synthesis, 8-12 h. The peak effects were observed 12-16 h after All exposure. over control, respectively) and of cellular protein content (9.7±7.3%, n = 7; 22.4±7.7%, n = 6; 24.8±4.9%, n = 4 over control, respectively).
We also studied the mitogenic influence of All on RASM cells. As described by previous investigations, we did not observe any significant effects of All on the cell number, 3H-thymidine incorporation, or 3H-thymidine labeling index determined by 3H-thymidine autoradiography (data not shown).
Antihypertrophic action of ANP on postconfluent RASM cells. Fig. 2 shows the effect of ANP on 3H-uridine and leucine incorporations of postconfluent RASM cells in the basal state in DSF media or stimulated by All (10-8 M). ANP inhibited RNA and protein syntheses of RASM cells. The maximal inhibition was seen at an ANP concentration of 100 nM, and an ED50 at 10-100 nM for both the basal state and All-stimulated state. The inhibitory action of ANP on 3H-uridine incorpora- (22) . Fig. 4 depicts TGF-flinduced RNA and protein syntheses in RASM cells and the effect of ANP on these parameters. TGF-/3 exhibited potent stimulatory action on 3H-uridine and leucine incorporations with the threshold of 40 pM for 3H-uridine and 400 pM for 3H-leucine incorporations, respectively. As shown in Fig. 4 and exhibits higher affinity to C-receptor (26, 27) . Because cGMP is thought to be the second messenger for the ANP-A and B receptors, we tested the effect of 8-bromo cGMP on 3H-uridine incorporation in the basal and All (10-8 M)-stimulated cells (Fig. 6 ). 8-Bromo cGMP (l03-l02 M) suppressed significantly the basal and All-stimulated rates of RNA synthesis.
Recently the role of protein kinase C in mediating protein synthesis in RASM cells has been suggested (28). Accordingly, we examined the possible involvement of protein kinase C in the antihypertrophic action of ANP. As shown in Table II (Fig. 1 A) is compatible with the temporal profile of the induction of these two growth factors. This result suggests that these growth factors are the possible mediator of All-induced hypertrophic action. In fact, we observed that the antisense oligonucleotides complementary to PDGF mRNA attenuates All-induced hypertrophy in RASM cells (30). TGF-# is reported to inhibit serum (1l-10%)-stimulated proliferation of RASM cells (ED50 = 2 pM) and concurrently induce cellular hypertrophy (22) . This means that TGF-4 may selectively inhibit serum-stimulated increase in DNA replication, while having little or no inhibition on serum-induced increase of protein synthesis. It has been supposed that TGF-fl may be a mediator of smooth muscle cell growth in vivo during wound repair and atherogenesis (10). We observed in the present study the potent stimulatory effect of TGF-3 on RNA and protein syntheses in RASM cells (Fig. 4) The concentration of ANP employed in this study exceeds the circulating level of plasma ANP encountered in physiological or pathophysiological conditions (34-36). However, we have previously studied the degradation of ANP in proteinase inhibitor-and EDTA-free culture media and showed that 80-90% of ANP immunoreactivity was lost during the initial 24-h incubation at 370C (37) . Therefore, the actual effective antihypertrophic concentration of ANP may be much lower. Thus it seems plausible to speculate that the ANP levels in the circulation may influence hypertrophic change of vascular smooth muscle cells in vivo. Furthermore, the local concentration of ANP accumulated in the tissue (e.g., blood vessel) may be much higher than that in the plasma. Indeed, a prolonged infusion of ANP (20 ,ug/kg per hr) to rats induced atrophy of zona glomerulosa cells of rat adrenals and lowered the plasma concentration of aldosterone without provoking significant changes in plasma renin activity, indicating that ANP exerted inhibitory effects on growth of rat zona glomerulosa in vivo (38).
As for 3H-uridine incorporation, ANP showed more pronounced inhibitory effect in the basal state rather than Allstimulated state (Fig. 2) . This phenomenon is comparable to the observation that the degree of relaxation of norepinephrine-contracted aorta produced by nitroprusside or 8-bromo cGMP was dependent on the dose of norepinephrine (39) . At higher concentrations of norepinephrine, less relaxation was seen for nitroprusside or 8-bromo cGMP than at lower concentration of norepinephrine. This result suggests that ANP exerts its antihypertrophic effect via the intracellular signaling pathway independent of All-specific activation pathway for hypertrophy. Indeed, ANP also showed the inhibitory effect on hypertrophy induced by TGF-fl, a potent hypertrophic factor, as well as by All. Therefore, these experiments indicate a more generalized inhibitory effect of ANP on the hypertrophy of vascular smooth muscle cells.
Recently, molecular cloning has defined three types of natriuretic peptide receptors: the ANP-C receptor of relative molecular mass 60-70 K, which is not coupled to cGMP production and may function in the clearance of ANP (25, 26) (40) . In the present paper, we studied the receptor subtype that mediates the growth inhibiting effect ofANP. Our data showed that C-ANP [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , which shows much higher affinity to the ANP-C receptor than the guanylate cyclasecoupled receptors (26, 27) , exerted little effect on the hypertrophy of RASM cells compared to ANP (Fig. 5) . This result suggests that the antihypertrophic effect of ANP is mediated by a guanylate cyclase-coupled receptor(s) (the ANP-A or B receptor). Because the exogenous administration of a cGMP analogue, 8-bromo cGMP, mimicked the ANP effect (Fig. 6) , the intracellular second messenger responsible for the antihypertrophic action of ANP seems to be cGMP. Indeed, recent data demonstrated that nitric oxide-generating vasodilators and 8-bromo cGMP can inhibit the proliferation of RASM cells (41) .
Involvement of protein kinase C pathway in cell growth has been postulated (28). Indeed, our data show that PMA increased the rate of RNA synthesis (Table II) . In the present study, ANP Antihypertrophic Action ofAtrial Natriuretic Polypeptide 1695 ANP still exerted its inhibitory effect on RNA synthesis. Thus, the antihypertrophic action of ANP appeared not to be dependent on protein kinase C activity. However, because it is also known that there is a protein kinase C isoform that is resistant to down-regulation in the rabbit aortic smooth muscle cells (42) , the involvement of protein kinase C activity in the antihypertrophic action of ANP cannot be completely ruled out. The elucidation of cellular mechanisms by which ANP inhibits hypertrophy of vascular smooth muscle cells awaits further investigation.
The present study demonstrates that ANP acts both as an antiproliferative as well as an antihypertrophic factor. These properties differ from those of TGF-f which inhibits serum stimulated cell proliferation by prolonging cell-cycling time or inducing G2 arrest, thereby increasing cell mass without division (22) . In contrast, ANP exerts inhibitory effects, not only on DNA replication and cell division, but also on RNA and protein syntheses that mediate the increase in cell mass.
Vascular hypertrophy in hypertension is usually an adaptive process in response to increased arterial wall stress. However, the resultant increase in the wall-to-lumen ratio can lead to an amplified vasoconstrictive response to contractile agonists and may perpetuate hypertension. In hypertension, augmented secretion of ANP, which is not only a vasorelaxant but also an antihypertrophic peptide, may prevent the progression of hypertension by inhibiting the vascular hypertrophy, as well as reducing the vascular tone (9) . The angiotensin converting enzyme inhibitor, captopril, not only reduced aortic smooth muscle cell contents in SHR (19) and two-kidney, one-clip hypertensive rats (43), but also decreased cross-sectional wall area of arterioles in one-kidney, one-clip hypertensive rats (44) . These data indicate the crucial role of circulating and/or local renin angiotensin system(s) in the vascular growth of conduit and resistant vessels. The inhibition of All-induced hypertrophy by ANP in the present study further suggests the compensatory role of ANP in hypertensive vascular change and also suggests a novel functional antagonistic relationship between ANP and renin angiotensin systems on cell growth. In addition, the general antimitogenic and antihypertrophic actions ofANP demonstrated in the present study suggest further the potential value of this peptide in the therapeutic application for hypertension.
